Contents

Brolucizumab for Neovascular Age-Related Macular Degeneration (HAWK AND HARRIER)

January 1, 2021

Clinical Trial

HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.

Dugel PU, Singh RP, Koh A, Ogura Y, Weissgerber G, Gedif K, Jaffe GJ, Tadayoni R, Schmidt-Erfurth U, Holz FG.

Ophthalmology. 2021 Jan;128(1):89-99.
Full text | Metrics.

Main finding: Brolucizumab was noninferior to aflibercept in visual function at Week 96

 

  • Purpose: To demonstrate that brolucizumab is noninferior to fixed-dose aflibercept with respect to the change in BCVA from baseline
  • Study type: Randomized controlled trial
  • Condition: CNV secondary to AMD

Participants: ≥50 years, active CNV secondary to AMD, VA 20/32-20/400

 

  • n=1078 (HAWK), 739 (HARRIER)

 

Intervention:

 

Group 1: Brolucizumab 3mg
-3 monthly doses then q12 weekly (adjust to q8 weekly if disease activity present)
Group 2: Brolucizumab 6mg
-3 monthly doses then q12 weekly (adjust to q8 weekly if disease activity present)
Group 3: Intravitreal Aflibercept 2mg q8weekly

 

Group 3: Sham PDT + Intravitreal Ranibizumab 0.5mg monthly

Brolucizumab was noninferior to aflibercept in visual function at Week 96
At week 92 there was a 45.4% and 38.6% probability for brolucizumab 6mg patients of maintaining on q12w in HAWK and HARRIER, respectively.

Outcomes Group BRO 3mg BRO 6mg AFLI 2mg
VA change HAWK +5.6 +5.9 +5.3
HARRIER +6.1 +6.6

Share This Article :

Updated on March 7th, 2022

Source Archive

© 2024 - sourceshed